X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (270) 270
Newspaper Article (30) 30
Book Review (13) 13
Publication (11) 11
Patent (8) 8
Conference Proceeding (6) 6
Dissertation (2) 2
Book / eBook (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (71) 71
index medicus (65) 65
multiple myeloma (59) 59
male (50) 50
middle aged (46) 46
female (42) 42
aged (41) 41
hematology (39) 39
adult (31) 31
bortezomib (30) 30
aged, 80 and over (25) 25
multiple myeloma - drug therapy (24) 24
oncology (24) 24
thalidomide (20) 20
dexamethasone (17) 17
survival (17) 17
prognosis (16) 16
analysis (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
therapy (14) 14
antineoplastic agents - therapeutic use (13) 13
multiple myeloma - diagnosis (13) 13
multiple myeloma - genetics (13) 13
treatment outcome (13) 13
follow-up studies (12) 12
melphalan (12) 12
multiple myeloma - pathology (12) 12
remission induction (12) 12
cancer (11) 11
multiple myeloma - mortality (11) 11
retrospective studies (11) 11
stem-cell transplantation (11) 11
bone marrow (10) 10
diagnosis (10) 10
multiple myeloma - therapy (10) 10
thalidomide - analogs & derivatives (10) 10
thalidomide - therapeutic use (10) 10
care and treatment (9) 9
dexamethasone - administration & dosage (9) 9
hematology, oncology and palliative medicine (9) 9
lenalidomide (9) 9
rituximab (9) 9
cytogenetics (8) 8
diagnosis, differential (8) 8
disease progression (8) 8
disease-free survival (8) 8
kaplan-meier estimate (8) 8
neoplasm staging (8) 8
patients (8) 8
plasma cells (8) 8
recurrence (8) 8
biomarkers (7) 7
chromosome aberrations (7) 7
flow cytometry (7) 7
hemic and lymphatic diseases (7) 7
medicine (7) 7
medicine, research & experimental (7) 7
monoclonal gammopathy (7) 7
monoclonal gammopathy of undetermined significance - diagnosis (7) 7
myeloma (7) 7
risk (7) 7
stem cells (7) 7
transplantation (7) 7
abridged index medicus (6) 6
angiogenesis (6) 6
boronic acids - therapeutic use (6) 6
chemotherapy (6) 6
disease (6) 6
drug therapy (6) 6
multiple-myeloma (6) 6
progression (6) 6
pyrazines - therapeutic use (6) 6
stem cell transplantation (6) 6
survival analysis (6) 6
survival rate (6) 6
universities and colleges (6) 6
anakinra (5) 5
bone marrow - pathology (5) 5
boronic acids - administration & dosage (5) 5
cladribine - therapeutic use (5) 5
czech republic (5) 5
expression (5) 5
gammopathy (5) 5
leukemia (5) 5
malignancy (5) 5
medicine, general & internal (5) 5
minimal residual disease (5) 5
monoclonal gammopathy of undetermined significance - genetics (5) 5
multiple myeloma - blood (5) 5
prednisone (5) 5
pyrazines - administration & dosage (5) 5
real-time polymerase chain reaction (5) 5
thalidomide - administration & dosage (5) 5
antineoplastic agents - administration & dosage (4) 4
antineoplastic combined chemotherapy protocols (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
case-control studies (4) 4
chronique (4) 4
combination (4) 4
combined modality therapy (4) 4
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (212) 212
French (75) 75
Czech (37) 37
Slovak (4) 4
German (2) 2
Dutch (1) 1
Portuguese (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 27 - 38
Journal Article
Terrain, ISSN 0760-5668, 2018, Volume 69, pp. 58 - 75
Journal Article
Terrain, ISSN 0760-5668, 04/2018, Issue 69, p. 58
Cet article traite de la capacité des fantômes à faire devenir autre ; des vivants et des morts dans un village sibérien ; de ceux qui adhèrent à l’existence... 
Death & dying | Ghosts | Reflexivity | Ontology | Otherness | Cultural anthropology
Journal Article
Journal Article
Blood Reviews, ISSN 0268-960X, 03/2019, Volume 34, p. 56
Multiple myeloma, which ranks as the second most common hematological malignancy, is known for its great genetic heterogeneity. One pathway, however, stands... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2016, Volume 374, Issue 17, pp. 1621 - 1634
The addition of the oral proteasome inhibitor ixazomib to a regimen of lenalidomide plus dexamethasone led to a significant prolongation of progression-free... 
SUPERIORITY | MEDICINE, GENERAL & INTERNAL | CARFILZOMIB | RANDOMIZED PHASE-3 | THERAPY | PROTEASOME INHIBITOR MLN9708 | QUALITY-OF-LIFE | BORTEZOMIB | THALIDOMIDE | ANTITUMOR-ACTIVITY | TRANSPLANTATION | Glycine - analogs & derivatives | Glycine - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Boron Compounds - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Exanthema - chemically induced | Aged, 80 and over | Adult | Glycine - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Administration, Oral | Kaplan-Meier Estimate | Proportional Hazards Models | Thrombocytopenia - chemically induced | Thalidomide - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Boron Compounds - adverse effects | Aged | Care and treatment | Dosage and administration | Dexamethasone | Multiple myeloma | Thrombocytopenia | Inhibitor drugs | Risk groups | Drug therapy | Peripheral neuropathy | Survival | Patients | Drug dosages | Proteasome inhibitors | Quality of life | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2019, Volume 187, Issue 4, pp. 447 - 458
Summary Multiple myeloma (MM) is a malignancy with varying survival outcomes and drivers of disease progression. Existing MM staging tools were developed using... 
overall survival | relapsed | multiple myeloma | risk stratification | algorithm | Algorithms | Risk groups | Multiple myeloma | Health risks | Risk | Malignancy | Health risk assessment | Patients | Survival
Journal Article
European Journal of Haematology, ISSN 0902-4441, 09/2017, Volume 99, Issue 3, pp. 223 - 233
Journal Article
by Dimopoulos, Meletios A and Dimopoulos, Athanasios and Gay, Francesca and Schjesvold, Fredrik and Beksac, Meral and Hajek, Roman and Weisel, Katja Christina and Weisel, Katja and Goldschmidt, Hartmut and Maisnar, Vladimir and Moreau, Philippe and Min, Chang Ki and Pluta, Andrzej and Pluta, Agnieszka and Chng, Wee Joo and Chng, Wee-Joo and Kaiser, Martin and Zweegman, Sonja and Mateos, Maria-Victoria and Mateos, Maria Victoria and Spencer, Andrew and Iida, Shinsuke and Morgan, Gareth and Suryanarayan, Kaveri and Teng, Zhaoyang and Skacel, Tomas and Palumbo, Antonio and Dash, Ajeeta B and Gupta, Neeraj and Labotka, Richard and Rajkumar, S Vincent and Bar, Daniel and Basso, Alfredo and Fantl, Dorotea and He, Simon and Horvath, Neomi and Lee, Cindy and Lee, Jae Hoon and Rowlings, Phillip and Taylor, Kerry and Cochrane, Tara and Kwok, Fiona and Ramanathan, Sundreswran and Agis, Hermine and Zojer, Niklas and Kentos, Alain and Offner, Fritz and Van Droogenbroeck, Jan and Wu, Ka Lung and Maiolino, Angelo and Martinez, Gracia and Zanella, Karla and Capra, Marcelo and Araújo, Sérgio and Gregora, Evzen and Pour, Ludek and Scudla, Vlastimil and Spicka, Ivan and Abildgaard, Niels and Andersen, Niels and Jensen, Bo Amdi and Helleberg, Carsten and Plesner, Torben and Salomo, Morten and Svirskaite, Asta and Delarue, Richard and Blau, Igor and Schieferdecker, Aneta and Teleanu, Veronica and Munder, Markus and Röllig, Christoph and Salwender, Han-Juergen and Fuhrmann, Stephan and Duerig, Jan and Zeis, Matthias and Klein, Stefan and Reimer, Peter and Schmidt, Christian and Scheid, Christof and Mayer, Karin and Hoffmann, Martin and Sosada, Markus and Delimpasi, Sosana and Kyrtsonis, Mary-Christine and Anagnostopoulos, Achilleas and Nagy, Zsolt and Illés, Árpád and Egyed, Miklós and Borbényi, Zita and Mikala, Gabor and Dally, Najib and Horowitz, Netanel and Gutwein, Odit and Nemets, Anatoly and Vaxman, Iuliana and Shvetz, Olga and Trestman, Svetlana and Ruchlemer, Rosa and Nagler, Arnon and Tadmor, Tamar and ... and TOURMALINE-MM3 Study Grp and TOURMALINE-MM3 study group
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10168, pp. 253 - 264
Journal Article